1. Key Insights 2. Neuroendocrine Tumors Epidemiology Overview at a Glance 2.1. Market (%) Distribution of Neuroendocrine Tumors in 2017 2.2. Market (%) Distribution of Neuroendocrine Tumors in 2028 3. Disease Background and Overview: Neuroendocrine Tumors (NET) 3.1. Introduction 3.2. Classification of Neuroendocrine Tumors 3.3. Causes 3.4. Risk Factors 3.5. Symptoms 3.6. Pathophysiology 3.7. Diagnosis 3.7.1. Grading of NETs: 3.7.2. Staging of NETs: 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. 7MM Total Prevalent Patient Population of NETs 4.3. Total Incident Patient Population of NETs 5. Country Wise-Epidemiology of NETs 5.1. United States 5.1.1. Total Prevalent Cases of NETs in the United States 5.1.2. Total Incident Cases of NETs in the United States 5.1.3. Diagnosed prevalent cases of NETs in the United States 5.1.4. Symptom based classification of NETs 5.1.5. Diagnosed prevalent cases based on Malignancy 5.1.6. Site-specific prevalent cases of NETs 5.1.7. Grade-wise prevalent cases of NETs 5.1.8. Stage-wise prevalent cases of NETs 5.2. EU5 Countries 5.3. Germany 5.3.1. Total Prevalent Cases of NETs in Germany 5.3.2. Total Incident Cases of NETs in Germany 5.3.3. Diagnosed prevalent cases of NETs in Germany 5.3.4. Symptom based classification of NETs 5.3.5. Diagnosed prevalent cases based on Malignancy 5.3.6. Site-specific prevalent cases of NETs 5.3.7. Grade-wise prevalent cases of NETs 5.3.8. Stage-wise prevalent cases of NETs 5.4. France 5.4.1. Total Prevalent Cases of NETs in France 5.4.2. Total Incident Cases of NETs in France 5.4.3. Diagnosed prevalent cases of NETs in France 5.4.4. Symptom based classification of NETs 5.4.5. Diagnosed prevalent cases based on Malignancy 5.4.6. Site-specific prevalent cases of NETs 5.4.7. Grade-wise prevalent cases of NETs 5.4.8. Stage-wise prevalent cases of NETs 5.5. Italy 5.5.1. Total Prevalent Cases of NETs in Italy 5.5.2. Total Incident Cases of NETs in Italy 5.5.3. Diagnosed prevalent cases of NETs in Italy 5.5.4. Symptom based classification of NETs 5.5.5. Diagnosed prevalent cases based on Malignancy 5.5.6. Site-specific prevalent cases of NETs 5.5.7. Grade-wise prevalent cases of NETs 5.5.8. Stage-wise prevalent cases of NETs 5.6. Spain 5.6.1. Total Prevalent Cases of NETs in Spain 5.6.2. Total Incident Cases of NETs in Spain 5.6.3. Diagnosed prevalent cases of NETs in Spain 5.6.4. Symptom based classification of NETs 5.6.5. Diagnosed prevalent cases based on Malignancy 5.6.6. Site-specific prevalent cases of NETs 5.6.7. Grade-wise prevalent cases of NETs 5.6.8. Stage-wise prevalent cases of NETs 5.7. United Kingdom 5.7.1. Total Prevalent Cases of NETs in the UK 5.7.2. Total Incident Cases of NETs in the UK 5.7.3. Diagnosed prevalent cases of NETs in the UK 5.7.4. Symptom based classification of NETs 5.7.5. Diagnosed prevalent cases based on Malignancy 5.7.6. Site-specific prevalent cases of NETs 5.7.7. Grade-wise prevalent cases of NETs 5.7.8. Stage-wise prevalent cases of NETs 5.8. Japan 5.8.1. Total Prevalent Cases of NETs in Japan 5.8.2. Total Incident Cases of NETs in Japan 5.8.3. Diagnosed prevalent cases of NETs in Japan 5.8.4. Symptom based classification of NETs 5.8.5. Diagnosed prevalent cases based on Malignancy 5.8.6. Site-specific prevalent cases of NETs 5.8.7. Grade-wise prevalent cases of NETs 5.9. Stage-wise prevalent cases of NETs 6. Treatment Algorithm 7. Unmet needs 8. Marketed Products 8.1. Afinitor (Everolimus): Novartis 8.1.1. Product Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Other development activities 8.1.5. Safety and Efficacy 8.1.6. Advantages and Disadvantages 8.1.7. Product Profile 8.2. Sutent (Sunitinib Malate): Pfizer 8.2.1. Product Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Other development activities 8.2.5. Safety and Efficacy 8.2.6. Advantages and Disadvantages 8.2.7. Product Profile To be continued in the report…. 9. Emerging Drugs 9.1. Key Cross Competition 9.2. 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen 9.2.1. Product Description 9.2.2. Product Profile 9.2.3. Product Development Activities 9.2.4. Clinical development 9.2.5. Safety and Efficacy 9.3. AMG 479: Amgen 9.3.1. Product Description 9.3.2. Product Profile 9.3.3. Product Development Activities 9.3.4. Clinical Development 9.3.5. Safety and Efficacy 9.3.6. Advantages and Disadvantages 9.4. Anlotinib: Advenchen Laboratories 9.4.1. Product Description 9.4.2. Product Profile 9.4.3. Product Development Activities 9.4.4. Clinical Development To be continued in the report…. 10. Neuroendocrine Tumors: 7 Major Market Analysis 10.1. Key Findings 10.2. Market Size of Neuroendocrine Tumors (NETs) in 7MM 11. Market Outlook by Country 12. The United States: Market Outlook 12.1. United States Market Size 12.1.1. Total Market size of NETs 12.1.2. Market Size by Therapies 13. EU-5 Countries: Market Outlook 13.1. Germany 13.1.1. Total Market size of NETs 13.1.2. Market Size by Therapies 13.2. France 13.2.1. Total Market size of NETs 13.2.2. Market Size by Therapies 13.3. Italy 13.3.1. Total Market size of NETs 13.3.2. Market Size by Therapies 13.4. Spain 13.4.1. Total Market size of NETs 13.4.2. Market Size by Therapies 13.5. United Kingdom 13.5.1. Total Market size of NETs 13.5.2. Market Size by Therapies 13.6. Japan: Market Outlook 13.6.1. Total Market size of NETs 13.6.2. Market Size by Therapies 14. Market Drivers 15. Market Barriers 16. Appendix 16.1. Report Methodology 17. DelveInsight Capabilities 18. Disclaimer 19. About DelveInsight

Table 1: Secondary causes of nephrotic syndrome Table 2: Systems of nomenclature for NETs Table 3: Grading systems for NETs Table 4: Total Prevalent Population of NETs in the 7MM (2017-2028) Table 5: Total Incident Population of NETs in the 7MM (2017-2028) Table 6: Total Prevalent Cases of NETs in the United States (2017-2028) Table 7: Total Incident Cases of NETs in the United States (2017-2028) Table 8: Diagnosed prevalent cases of NETs in the United States (2017-2028) Table 9: Symptom based classification of NETs in the United States (2017-2028) Table 10: Diagnosed prevalent cases based on Malignancy in the United States (2017-2028) Table 11: Site-specific prevalent cases of NETs in the United States (2017-2028) Table 12: Grade-wise prevalent cases of NETs in the United States (2016-2027) Table 13: Stage-wise prevalent cases of NETs in the United States (2017-2028) Table 14: Total Prevalent Cases of NETs in Germany (2017-2028) Table 15: Total Incident Cases of NETs in Germany (2017-2028) Table 16: Diagnosed prevalent cases of NETs in Germany (2017-2028) Table 17: Symptom based classification of NETs in Germany (2017-2028) Table 18: Diagnosed prevalent cases based on Malignancy in Germany (2017-2028) Table 19: Site-specific prevalent cases of NETs in Germany (2017-2028) Table 20: Grade-wise prevalent cases of NETs in Germany (2017-2028) Table 21: Stage-wise prevalent cases of NETs in Germany (2017-2028) Table 22: Total Prevalent Cases of NETs in France (2017-2028) Table 23: Total Incident Cases of NETs in France (2017-2028) Table 24: Diagnosed prevalent cases of NETs in France (2017-2028) Table 25: Symptom based classification of NETs in France (2017-2028) Table 26: Diagnosed prevalent cases based on Malignancy in France (2017-2028) Table 27: Site-specific prevalent cases of NETs in France (2017-2028) Table 28: Grade-wise prevalent cases of NETs in France (2017-2028) Table 29: Stage-wise prevalent cases of NETs in France (2017-2028) Table 30: Total Prevalent Cases of NETs in Italy (2017-2028) Table 31: Total Incident Cases of NETs in Italy (2017-2028) Table 32: Diagnosed prevalent cases of NETs in Italy (2017-2028) Table 33: Symptom based classification of NETs in Italy (2017-2028) Table 34: Diagnosed prevalent cases based on Malignancy in Italy (2017-2028) Table 35: Site-specific prevalent cases of NETs in Italy (2017-2028) Table 36: Grade-wise prevalent cases of NETs in Italy (2017-2028) Table 37: Stage-wise prevalent cases of NETs in Italy (2017-2028) Table 38: Total Prevalent Cases of NETs in Spain (2017-2028) Table 39: Total Incident Cases of NETs in Spain (2017-2028) Table 40: Diagnosed prevalent cases of NETs in Spain (2017-2028) Table 41: Symptom based classification of NETs in Spain (2017-2028) Table 42: Diagnosed prevalent cases based on Malignancy in Spain (2017-2028) Table 43: Site-specific prevalent cases of NETs in Spain (2017-2028) Table 44: Grade-wise prevalent cases of NETs in Spain (2017-2028) Table 45: Stage-wise prevalent cases of NETs in Spain (2017-2028) Table 46: Total Prevalent Cases of NETs in the UK (2017-2028) Table 47: Total Incident Cases of NETs in the UK (2017-2028) Table 48: Diagnosed prevalent cases of NETs in the UK (2017-2028) Table 49: Symptom based classification of NETs in the UK (2017-2028) Table 50: Diagnosed prevalent cases based on Malignancy in the UK (2017-2028) Table 51: Site-specific prevalent cases of NETs in the UK(2017-2028) Table 52: Grade-wise prevalent cases of NETs in the UK (2017-2028) Table 53: Stage-wise prevalent cases of NETs in the UK (2017-2028) Table 54: Total Prevalent Cases of NETs in Japan (2017-2028) Table 55: Total Incident Cases of NETs in Japan (2017-2028) Table 56: Diagnosed prevalent cases of NETs in Japan (2017-2028) Table 57: Symptom based classification of NETs in Japan (2017-2028) Table 58: Diagnosed prevalent cases based on Malignancy in Japan (2017-2028) Table 59: Site-specific prevalent cases of NETs in Japan (2017-2028) Table 60: Grade-wise prevalent cases of NETs in Japan (2017-2028) Table 61: Stage-wise prevalent cases of NETs in Japan (2017-2028) Table 62: Phase III Drug Analysis Table 63: Phase I/II Drug Analysis Table 64: Phase I/II Drug Analysis Table 65: Phase I/II Drug Analysis Table 66: Phase I/II Drug Analysis Table 67: Lenvatinib, Clinical Trial Description, 2019 Table 68: Pasireotide, Clinical Trial Description, 2019 Table 69: Spartalizumab, Clinical Trial Description, 2019 Table 70: Tirapazamine, Clinical Trial Description, 2019 Table 71: PEN-221, Clinical Trial Description, 2019 Table 72: Sulfatinib, Clinical Trial Description, 2019 Table 73: Ibrutinib, Clinical Trial Description, 2019 Table 74: Ramucirumab, Clinical Trial Description, 2019 Table 75: ALT 803, Clinical Trial Description, 2019 Table 76: Talimogene laherparepvec, Clinical Trial Description, 2019 Table 77: Netazepide, Clinical Trial Description, 2019 Table 78: 7 Major Market Size of NETs in USD Million (2017-2028) Table 79: The US Market Size of NETs in USD Million (2017-2028) Table 80: Therapies Based market of NETs in the US, in USD Million (2017-2028) Table 81: Market Size of NETs in Germany, in USD Million (2017-2028) Table 82: Therapies Based market of NETs in Germany, in USD Million (2017-2028) Table 83: Market Size of NETs in France, in USD Million (2017-2028) Table 84: Therapies Based market of NETs in France, in USD Million (2017-2028) Table 85: Market Size of NETs in Italy, in USD Million (2017-2028) Table 86: Therapies Based market of NETs in Germany, in USD Million (2017-2028) Table 87: Market Size of NETs in Spain, in USD Million (2017-2028) Table 88: Therapies Based market of NETs in Spain, in USD Million (2017-2028) Table 89: Market Size of NETs in the UK, in USD Million (2017-2028) Table 90: Therapies Based market of NETs in UK, in USD Million (2017-2028) Table 91: Market Size of NETs in Japan, in USD Million (2017-2028) Table 92:Therapies Based market of NETs in Japan, in USD Million (2017-2028) Figure 1: Classification of Neuroendocrine Tumors Figure 2: Causes of Neuroendocrine Tumors Figure 3: Targeting critical signaling pathways in NETs Figure 4: Total Prevalent Population of NETs in the 7MM (2017-2028) Figure 5: Total Incident Population of NETs in the 7MM (2017-2028) Figure 6: Total Prevalent cases of NETs in the United States (2017-2028) Figure 7: Total Incident cases of NETs in the United States (2017-2028) Figure 8: Diagnosed prevalent cases of NETs in the United States (2017-2028) Figure 9: Symptom based classification of NETs in the United States (2017-2028) Figure 10: Diagnosed prevalent cases based on Malignancy in the United States (2017-2028) Figure 11: Site-specific prevalent cases of NETs in the United States (2017-2028) Figure 12: Grade-wise prevalent cases of NETs in the United States (2016-2027) Figure 13: Stage-wise prevalent cases of NETs in the United States (2017-2028) Figure 14: Total Prevalent cases of NETs in Germany (2017-2028) Figure 15: Total Incident cases of NETs in Germany (2017-2028) Figure 16: Diagnosed prevalent cases of NETs in Germany (2017-2028) Figure 17: Symptom based classification of NETs in Germany (2017-2028) Figure 18: Diagnosed prevalent cases based on Malignancy in Germany (2017-2028) Figure 19: Site-specific prevalent cases of NETs in Germany (2017-2028) Figure 20: Grade-wise prevalent cases of NETs in Germany (2017-2028) Figure 21: Stage-wise prevalent cases of NETs in Germany (2017-2028) Figure 22: Total Prevalent cases of NETs in the France (2017-2028) Figure 23: Total Incident cases of NETs in the France (2017-2028) Figure 24: Diagnosed prevalent cases of NETs in France (2017-2028) Figure 25: Symptom based classification of NETs in France (2017-2028) Figure 26: Diagnosed prevalent cases based on Malignancy in France (2017-2028) Figure 27: Site-specific prevalent cases of NETs in France (2017-2028) Figure 28: Grade-wise prevalent cases of NETs in France (2017-2028) Figure 29: Stage-wise prevalent cases of NETs in France (2017-2028) Figure 30: Total Prevalent cases of NETs in the Italy (2017-2028) Figure 31: Total Incident cases of NETs in the Italy (2017-2028) Figure 32: Diagnosed prevalent cases of NETs in Italy (2017-2028) Figure 33: Symptom based classification of NETs in Italy (2017-2028) Figure 34: Diagnosed prevalent cases based on Malignancy in Italy (2017-2028) Figure 35: Site-specific prevalent cases of NETs in Italy (2017-2028) Figure 36: Grade-wise prevalent cases of NETs in Italy (2017-2028) Figure 37: Stage-wise prevalent cases of NETs in Italy (2017-2028) Figure 38: Total Prevalent cases of NETs in the Spain (2017-2028) Figure 39: Total Incident cases of NETs in the Spain (2017-2028) Figure 40: Diagnosed prevalent cases of NETs in Spain (2017-2028) Figure 41: Symptom based classification of NETs in Spain (2017-2028) Figure 42: Diagnosed prevalent cases based on Malignancy in Spain (2017-2028) Figure 43: Site-specific prevalent cases of NETs in Spain (2017-2028) Figure 44: Grade-wise prevalent cases of NETs in Spain (2017-2028) Figure 45: Stage-wise prevalent cases of NETs in Spain (2017-2028) Figure 46: Total Prevalent cases of NETs in the UK (2017-2028) Figure 47: Total Incident cases of NETs in the UK (2017-2028) Figure 48: Diagnosed prevalent cases of NETs in the UK (2017-2028) Figure 49: Symptom based classification of NETs in the UK (2017-2028) Figure 50: Diagnosed prevalent cases based on Malignancy in the UK (2017-2028) Figure 51: Site-specific prevalent cases of NETs in the UK (2017-2028) Figure 52: Grade-wise prevalent cases of NETs in the UK (2017-2028) Figure 53: Stage-wise prevalent cases of NETs in the UK (2017-2028) Figure 54: Total Prevalent cases of NETs in Japan (2017-2028) Figure 55: Total Incident cases of NETs in Japan (2017-2028) Figure 56: Diagnosed prevalent cases of NETs in Japan (2017-2028) Figure 57: Symptom based classification of NETs in the Japan (2017-2028) Figure 58: Diagnosed prevalent cases based on Malignancy in Japan (2017-2028) Figure 59: Site-specific prevalent cases of NETs in Japan (2017-2028) Figure 60: Grade-wise prevalent cases of NETs in Japan (2017-2028) Figure 61: Stage-wise prevalent cases of NETs in Japan (2017-2028) Figure 62: Treatment of Neuroendocrine tumors Figure 63: Unmet needs Figure 64: 7 Major Market Size of NETs in USD Million (2017-2028) Figure 65: Market Size of NETs in the US, USD Millions (2017-2028) Figure 66: Therapies Based market of NETs in the US in USD Million (2017-2028) Figure 67: Market Size of NETs in Germany, USD Millions (2017-2028) Figure 68: Therapies Based market of NETs in Germany, in USD Million (2017-2028) Figure 69: Market Size of NETs in France, USD Millions (2017-2028) Figure 70: Therapies Based market of NETs in France, in USD Million (2017-2028) Figure 71: Market Size of NETs in Italy, USD Millions (2017-2028) Figure 72: Therapies Based market of NETs in Italy, in USD Million (2017-2028) Figure 73: Market Size of NETs in Spain, USD Millions (2017-2028) Figure 74: Therapies Based market of NETs in Spain, in USD Million (2017-2028) Figure 75: Market Size of NETs in the UK, USD Millions (2017-2028) Figure 76: Therapies Based market of NETs in the UK, in USD Million (2017-2028) Figure 77: Market Size of NETs in Japan, USD Millions (2017-2028) Figure 78: Therapies Based market of NETs in Japan, in USD Million (2017-2028) Figure 79: Market Drivers Figure 80:Market Barriers

• 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen • AMG 479: Amgen • Anlotinib: Advenchen Laboratories • Carfilzomib: Amgen • ATG-008: Antengene • Ipilimumab: Bristol-Myers Squibb • Ribociclib: Novartis • Pembrolizumab: Merck • RRx-001: EpicentRx • Axitinib: Pfizer • Cabozantinib: Exelixis • CAM2029: Camurus • Atezolizumab and Bevacizumab: Genentech • Lenvatinib: Eisai • Pasireotide LAR: Novartis • Spartalizumab: Novartis • Tirapazamine: Teclison • PEN221: Tarveda Therapeutics • Sulfatinib: Hutchison China MediTech • Ibrutinib: Pharmacyclics • Ramucirumab: Eli Lilly • ALT 803: Altor Biosciences • Talimogene laherparepvec: Amgen • Netazepide: Trio Medicines